Contents

OPINION REVIEW

249 Augmenting prostate magnetic resonance imaging reporting to incorporate diagnostic recommendations based upon clinical risk calculators
Gupta K, Perchik JD, Fang AM, Porter KK, Rais-Bahrami S

MINIREVIEWS

256 Advanced magnetic resonance imaging findings in salivary gland tumors
Gökçe E, Beyhan M

272 Amebic liver abscess: Clinico-radiological findings and interventional management
Priyadarshi RN, Kumar R, Anand U

286 Progress in interventional radiology treatment of pulmonary embolism: A brief review

ORIGINAL ARTICLE

Retrospective Study

293 Imaging volumes during COVID-19: A Victorian health service experience

311 Triple rule-out computed tomography angiography: Evaluation of acute chest pain in COVID-19 patients in the emergency department
Bahadir S, Aydon S, Kantarcı M, Unver E, Karavas E, Şenbil DC
ABOUT COVER
Editorial Board Member of World Journal of Radiology, Alexander B Konovalov, PhD, Associate Professor, Leading Scientist, Russian Federal Nuclear Center - Zababakhin Institute of Applied Physics, Snezninsk 456770, Russia. a_konov@mail.vega-int.ru

AIMS AND SCOPE
The primary aim of World Journal of Radiology (WJR, World J Radiol) is to provide scholars and readers from various fields of radiology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.
WJR mainly publishes articles reporting research results and findings obtained in the field of radiology and covering a wide range of topics including state of the art information on cardiopulmonary imaging, gastrointestinal imaging, genitourinary imaging, musculoskeletal imaging, neuroradiology/head and neck imaging, nuclear medicine and molecular imaging, pediatric imaging, vascular and interventional radiology, and women's imaging.

INDEXING/ABSTRACTING
The WJR is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for WJR as 0.48.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Rui-Rui Wu; Production Department Director: Xie Gao; Editorial Office Director: Jia-Ping Yuan.
Progress in interventional radiology treatment of pulmonary embolism: A brief review

Alessandro Posa, Pierluigi Barbieri, Giulia Mazza, Alessandro Tanzilli, Roberto Iezzi, Riccardo Manfredi, Cesare Colosimo

Abstract

Pulmonary embolism represents a common life-threatening condition. Prompt identification and treatment of this pathological condition are mandatory. In cases of massive pulmonary embolism and hemodynamic instability or right heart failure, interventional radiology treatment for pulmonary embolism is emerging as an alternative to medical treatment (systemic thrombolysis) and surgical treatment. Interventional radiology techniques include percutaneous endovascular catheter directed therapies as selective thrombolysis and thrombus aspiration, which can prove useful in cases of failure or infeasibility of medical and surgical approaches.

Key Words: Pulmonary embolism; Interventional radiology; Thrombolysis; Thrombectomy; Catheter directed therapy; Endovascular
INTRODUCTION

Venous thromboembolism, clinically presenting as deep vein thrombosis or pulmonary embolism (PE), is the third most frequent acute cardiovascular syndrome globally, after myocardial infarction and stroke[1]. Approximately one-third of all patients with a new diagnosis of venous thromboembolism have PE, with or without deep vein thrombosis[2]. PE can be defined as the occlusion of the pulmonary arteries or its branches with embolic material (thrombus, air, fat or amniotic fluid) that originates elsewhere in the body. Most commonly, the cause is a thrombus arising from the deep veins of the lower extremities, which travels to the pulmonary circulation.

Diagnosis of PE can be subtle, as there are no specific symptoms, and clinical presentation varies widely, ranging from asymptomatic to sudden cardiac death, which is seen in 25%-30% of patients[3]. There have been many advances in the field of PE in the recent decades. The development of new diagnostic and therapeutic strategies, including medical and surgical treatment as well as endovascular therapy, has led to an increasing complexity of patient treatment and, consequently, to the need of optimizing the management of this serious condition.

PHYSIOPATHOLOGY

PE, by definition, is characterized by the presence of emboli in the pulmonary arterial circulation. Most emboli originate as thrombi in the deep veins of the lower extremities; the most common site of thrombosis is represented by the calf veins, followed by femoro-popliteal veins and iliac veins. Less frequently, emboli arise from upper extremity veins and are typically associated with central venous catheters, intracardiac devices, malignancy or venous trauma. A smaller percentage of PE is caused by pelvic deep vein thrombosis, but they are generally associated with a predisposing factor such as pelvic infection, pelvic surgery or pregnancy[4]. When 25%-30% of the pulmonary vasculature is obliterated by a thrombo-embolus, pulmonary artery pressure begins to increase. However, the mechanical obstruction is not the only element leading to pulmonary hypertension: the disruption of the alveolar-capillary membrane by the thrombi results in a decrease of oxygen diffusion, with subsequent hypoxia and release of vasoconstrictors that contribute to the acute development of pulmonary hypertension[5]. The increase of pressure in the pulmonary artery determines heterogeneity of pulmonary perfusion, leading to the simultaneous presence of hypo- and hyperperfused areas; there will be an imbalance between ventilation and perfusion, generating hypoxemia[6].

Moreover, PE can have significant cardiac and hemodynamic consequences, related to the size of emboli and the presence or absence of underlying cardiopulmonary disease. In healthy patients, the mean pulmonary artery pressure can be up to 40 mmHg acutely; right ventricle (RV) failure ensues when 50%-75% of pulmonary arteries are obstructed[7]. When the degree of pulmonary artery obstruction exceeds 50%-75%, the right heart dilates and the combination of the increased wall stress and cardiac ischemia impair RV function and left ventricular (LV) output, leading to hypotension[8]. The presence of pre-existing cardiopulmonary disease results in diminished pulmonary vascular reserve and hemodynamic compromise at a lower level of pulmonary arterial obstruction.

PULMONARY EMBOLISM RISK STRATIFICATION

The American Heart Association (AHA) and the European Society of Cardiology (ESC) classified PE according to its severity, identifying three main categories[1,9].

Patients with massive (AHA) or high risk (ESC) PE present with hypotension, defined as a systolic blood pressure lower than 90 mmHg, or a drop of > 40 mmHg for at least 15 min or need for vasopressor support.

Submassive (AHA) or intermediate risk (ESC) classifications slightly differ as, according to AHA, patients with submassive PE present with an RV strain with no hypotension. RV strain is defined as: RV dysfunction on echocardiography or computed tomography pulmonary angiography, and RV injury identified by an increase in cardiac biomarkers as troponins or brain natriuretic hormone. On the other side, the ESC criteria for intermediate-risk PE include patients with a simplified Pulmonary Embolism Severity Index score ≥ 1, regardless of RV strain. The Pulmonary Embolism Severity Index score is based on the patient’s age, comorbidities, heart rate, blood pressure and oxygen saturation. Moreover, the ESC subclassifies intermediate-risk patients in two groups based on RV dysfunction and RV injury (intermediate risk–high) or only one or neither of these findings (intermediate risk–low).

Low risk patients, according to both AHA and ESC, do not meet criteria for the abovementioned risk categories.
**MEDICAL AND SURGICAL TREATMENT**

Severe PE leads to hypoxaemia due to the ventilation-perfusion mismatch. Therefore, it is advised to use oxygen in patients with oxygen saturation < 90%. High-flow oxygen and mechanical ventilation should be taken in consideration when extreme hemodynamic instability is present (i.e. cardiac arrest), even though obtaining a good hypoxemia correction is not completely possible without PE reperfusion techniques[10,11]. Intubation should be considered in patients who are not manageable with noninvasive ventilation[1].

Acute RV failure is a cause of death in high-risk PE patients due to the reduction of cardiac output. When low central venous pressure is present, modest fluid challenge (< 500 mL) could be an option, increasing cardiac index in these patients[12]. On the other hand, fluid challenge could also over-distend the RV, leading to a reduction of cardiac output. Therefore, it is recommended to use it wisely[13]. If signs of elevated central venous pressure are present, no volume loading is advised. Vasopressors are often necessary in association with reperfusion treatment (medical, surgical or interventional). Norepinephrine leads to an improvement in coronary perfusion and ventricular systolic interaction, without changing pulmonary vascular resistance[14]; the use of norepinephrine should be limited in patients with cardiogenic shock.

Temporary extracorporeal membrane oxygenation could be used in patients with a high-risk PE, cardiac arrest and circulatory collapse, but its use needs to be further tested with clinical trials[15,16].

Acute PE may lead to cardiac arrest, in which case the current advanced life support guidelines have to be followed[17].

Moreover, in patients with intermediate to high risk of PE, it is advised to start subcutaneous anticoagulation while waiting for diagnostic tests, usually with low-molecular weight heparin, fondaparinux or unfractionated heparin[18]. Clinical trials with non-vitamin K antagonist oral anticoagulants are ongoing.

Vitamin K antagonists are vastly used for oral anticoagulation in recent years; when vitamin K antagonists are used, low-molecular weight heparin or unfractionated heparin should be continued along with oral anticoagulants for more than 5 d until the International Normalized Ratio value reaches 2-3 for 2 d[19].

Regarding reperfusion treatment, systemic thrombolysis leads to fast improvement of the pulmonary obstruction and cardiovascular parameters in patients with PE compared to medical treatment alone[20, 21]. The best results are obtained when reperfusion treatment starts 48 h after symptoms onset; however thrombolysis could be useful even after 6-14 d[22]. Intravenous administration of recombinant tissue-type plasminogen activator is preferred to first generation thrombolytic agents (i.e. urokinase)[23].

Surgical embolectomy in patients with acute PE is performed through cardiopulmonary bypass, with incision of the pulmonary arteries and clots removal. This approach is advised in high-risk PE and in selected intermediate-risk patients[1,24].

**ENDOVASCULAR TREATMENTS: CURRENT EVIDENCE AND FUTURE PERSPECTIVES**

*Catheter directed thrombolysis*

Catheter directed thrombolysis (CDT) gives the advantage of locally delivering a high concentration of fibrinolytic agent to a great clot surface. This way, fibrinolytic dose can be greatly reduced compared to the systemic one, and side effects are therefore lower. A routine use diagnostic angiography catheter with multiple holes can be used to deliver the fibrinolytic agent and increase its local blood concentration. This could enhance the efficiency of fibrinolysis, reducing the risk of bleeding. Each pulmonary artery is catheterized with a multihole catheter, and a fibrinolytic agent such as tissue plasminogen activator is injected through the clot at a rate of 1 mg/h for 24 h in case of a unilateral PE (single device) and 1 mg/h for 12 h if bilateral PE (double device) (SEATTLE II Trial)[25]. A more recent trial, the OPTALYSE PE trial, analyzed the possibility to further lower the dose of tissue plasminogen activator with shorter infusions. The total dose was significantly lower, ranging from 4 to 12 mg per lung, and shorter infusion times (2 to 6 h)[26].

Efficient systemic administration of heparin is continued throughout the endovascular fibrinolysis procedure. Despite the lack of randomized trial studies comparing endovascular and systemic thrombolytic therapy, several comparative studies have been carried out. In a meta-analysis of Bloomer et al[27], the rate of intracranial hemorrhage with CDT was 0.35%, which is significantly lower than that reported with systemic thrombolytics in other randomized trials (1.46%). Bloomer et al[27] also found that the rate of major bleeding or vascular complication was 4.65%, and the observed mortality rate was 3.4% (12.9% in the massive PE group, 0.74% in the submassive PE group).

In addition, results of an American national registry enrolling 3107 patients who underwent systemic fibrinolytic treatment and 1319 patients undergoing CDT showed that the systemic thrombolysis group had increased rates of bleeding-related mortality (18.1% vs 8.4%), general mortality (14.9% vs 6.12%) and rehospitalization (10.6% vs 7.6%)[28]. According to these data, the risk of fatal bleeding is lower during CDT than in cases of systemic thrombolysis. This can be due to the higher (approximately four-fold)
The ongoing PE-TRACT and HI-PEITHO studies are designed to overcome this issue.

**Mechanical thrombectomy**

In cases of massive PE, the first aim should be to quickly declot the affected pulmonary artery to decrease pulmonary hypertension and the risk of RV failure. Initial fragmentation or thrombectomy by different devices (Table 1) can help reduce the thrombotic load and improve reperfusion. In addition, fragmentation of the clot exposes a greater surface of the thrombus, increasing the efficacy of local or systemic therapies[29].

Current catheters for mechanical thrombectomy or endovascular aspiration are classified based on the mechanism of action.

### Rheolytic

AngioJet (Boston Scientific, Massachusetts, United States) working mechanism is determined by aspiration of the thrombus using the Venturi-Bernoulli effect. It creates a suction effect with high-pressure jets in the catheter’s distal holes. Various complications (e.g., bradycardia and heart attack, severe hemoptysis, kidney failure as well as intra- and periprocedural deaths) were reported during the use of this device[30]; hence, the use of AngioJet as a first-approach treatment should be avoided. Currently the main indication of this product remains treatment of peripheral venous districts.

The Indigo CAT8 received Food and Drug Administration approval for PE treatment in December 2019. The system is being monitored to assess its safety even in real-world clinical practice, showing a low incidence of reports linked to the product[34].

**Rotational**

A relatively new device for treatment of PE is Aspirex (Straub, Wangs, Switzerland). Launched in mid-2010, the Aspirex catheter acts as an Archimedean screw that rotates inside the catheter lumen; this spiral mechanism provides an aspiration supplied by an active motor. Clinical results are promising; however, only recent studies with small cohorts of patients demonstrated its safety and efficacy, and there is a lack of randomized studies supporting this evidence[31]. Two European case series have been reported, with complete thrombus clearance observed in 83% to 88% of patients with intermediate- and high-risk PE[31,32].

**Aspiration**

The Indigo mechanical aspiration system (Penumbra, Alameda, United States) is an aspiration thrombectomy catheter system. A large caliber (8 French) catheter with a directional soft tip, allows easy aspiration of the clots in the pulmonary arteries due to the great suction power of a suction pump. Several studies are being performed to evaluate safety and efficacy of this device. The recent Indigo Aspiration System for Treatment of Pulmonary Embolism Trial (EXTRACT-PE), a prospective multicenter study on 119 patients demonstrated a significant reduction in the RV/LV ratio and a low major adverse event rate in submassive PE patients treated with the Indigo CAT8 aspiration system, with a reduction of administered intraprocedural thrombolytic drugs, which were avoided in 98.3% of patients[33]. The Indigo CAT8 received Food and Drug Administration approval for PE treatment in December 2019. The system is being monitored to assess its safety even in real-world clinical practice, showing a low incidence of reports linked to the product[34].

FlowTriever® System (Inari Medical) is another aspiration device. Its mechanism features three self-expanding nitinol mesh disks designed to engage, disrupt and deliver the clot to the Triever Aspiration Catheter for extraction. It has been evaluated in a recent single-arm multicenter trial involving 106 patients (FLARE Study) and appears safe and effective in patients with acute intermediate-risk PE, with significant improvement in RV/LV ratio and minimal major bleeding[35]. In 2021 Inari Medical, Inc. announced enrollment of the PEERLESS randomized controlled trial comparing the clinical outcomes of patients with intermediate-high risk PE treated with the company’s FlowTriever system vs CDT (NCT05111613). PEERLESS is a prospective, multicenter trial that will include up to 700 patients and 60 centers in the United States and Europe. It will be the first ever randomized controlled trial to compare mechanical thrombectomy to catheter-directed thrombolysis for the treatment of PE and aims to provide definitive data on interventional treatment options for these patients.

**Fragmentation**

The EKOSonic system (Boston Scientific, Massachusetts, United States) is an ultrasound-assisted catheter-directed thrombolysis system, which was specifically indicated for treatment of PE. The ultrasound waves that depart from the interior of the 5.4 French catheter can reach and treat the whole thrombus; in addition, fibrinolytic agent infusion can be performed from the catheter, combining the two treatment modalities. The functioning tip of the catheter can be of different lengths, with a range from 6 to 50 cm. Although it has been associated with a relatively safe and effective profile, the clinical benefits of this treatment when compared to classical CDT has yet to be proven[25]. Ultrasound-assisted thrombolysis was shown in a randomized trial named ULTIMA to determine faster decreases of the dose of fibrinolytic agent used in systemic thrombolysis. However, as these data are extracted from a national registry and not from randomized studies, they should cautiously be taken in consideration.

<table>
<thead>
<tr>
<th>Table 1 Main mechanical thrombectomy devices</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rheolytic</strong></td>
</tr>
<tr>
<td>AngioJet (Boston Scientific)</td>
</tr>
</tbody>
</table>

---
RV/LV ratio in patients with acute onset of intermediate-risk PE when compared to medical treatment, with no occurrence of major bleeding. However, the authors did not observe variations in 90-d patient mortality[36].

CONCLUSION

Actual ESC guidelines indicate that in high-risk or intermediate/high-risk patients (with RV dysfunction at transthoracic ultrasonography or at computed tomography pulmonary angiography or Pulmonary Embolism Severity Index greater than 1 and positive troponin test), reperfusion treatments should be performed, in association with prompt hemodynamic support[1]. However, systemic thrombolysis is actually considered as the first indication, and as literature evidence states surgical pulmonary embolectomy is recommended in patients with high-risk PE in whom systemic thrombolysis is contraindicated or has failed (level of evidence I). Percutaneous catheter-directed treatment has level of evidence IIa and therefore should be conditionally considered after failure or infeasibility of the abovementioned medical and surgical therapies[2].

Set up of a multidisciplinary team and of management protocols for high-risk and intermediate/high-risk patients with PE should be considered, to promptly and correctly address every PE case.

New perspectives

The 2021 announcement of the multicentric prospective PEERLESS randomized controlled trial comparing aspiration thrombectomy vs catheter-directed thrombolysis in up to 700 patients will provide real-life data on interventional radiology treatments for patients with intermediate/high-risk PE. At the same time, ultrasonography-assisted thrombolysis is proving valuable in intermediate/high-risk PE patients with good results and low complication rates[36]. However, more prospective studies are needed to shed light on the best interventional radiology treatment for this critical condition as well as to give the right place in the guidelines to these endovascular and mini-invasive techniques, on par to medical and surgical treatments.

FOOTNOTES

Author contributions: Posa A designed the research study; Posa A, Barbieri P, Tanzilli A and Mazza G performed the research and wrote the manuscript; Posa A, Iezzi R, Manfredi R and Colosimo C revised the manuscript; All authors have read and approved the final manuscript.

Conflict-of-interest statement: All the Authors have no conflict of interest to disclose.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Italy

ORCID number: Alessandro Posa 0000-0001-9617-3413; Roberto Iezzi 0000-0002-2791-481X; Riccardo Manfredi 0000-0002-4972-9500.

S-Editor: Liu JH
L-Editor: Filipodia
P-Editor: Liu JH

REFERENCES


